semaglutide news today 2025 New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Medicare, Medicaid to experiment with
Description
Metabolic improvements: Blood sugar regulation and cardiovascular support enhance overall wellness
Reviewed by a licensed US provider
Doses run from 0.25 mg through 2 mg for Ozempic and from 0.25 mg through 2.4 mg for Wegovy
A 2022 JAMA study on 338 adults who had overweight or obesity found that taking semaglutide and liraglutide, respectively, led to an average 15.8% and 6.4% loss in body weight over 68 weeks
Side effects tend to be dose-dependent and include nausea, vomiting, abdominal cramps, diarrhea, and a fishy body odor
Just be sure to give yourself extra time to allow for screening of these items
